A Pilot, Prospective, Non-randomized Study to Evaluate the Safety and Efficacy of Switches From Etravirine to Doravirine, in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance
Latest Information Update: 05 Jan 2023
Price :
$35 *
At a glance
- Drugs Doravirine (Primary) ; Etravirine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 26 Jan 2021 Planned End Date changed from 31 Dec 2022 to 1 Oct 2022.
- 26 Jan 2021 Planned primary completion date changed from 1 Jul 2021 to 14 Jul 2022.
- 26 Jan 2021 Status changed from not yet recruiting to recruiting.